In conclusion, AIM2 was found to inhibit ferroptosis and promotes RCC progression and sunitinib resistance; thus, AIM2 could serve as a prognostic biomarker for RCC progression and a therapeutic target for RCC treatment. This evidence concerns the gene AIM2 and renal cell carcinoma.